Role of ADHD medication in children with autism spectrum disorder. Pieter Hoekstra University of Groningen, Netherlands
|
|
- Eugene Thornton
- 5 years ago
- Views:
Transcription
1 Role of ADHD medication in children with autism spectrum disorder Pieter Hoekstra University of Groningen, Netherlands
2 Symptoms of ADHD are highly prevalent in children with ASD Two independent chart reviews reported that 59% (Goldstein & Schwebach, 2004) and 78% (Lee & Ousley, 2006), respectively, of referred children with ASD fulfilled full DSM IV criteria for an ADHD subtype.
3
4 Overlap between ADHD and Autism
5 ADHD comorbidity in ASD needs clinical attention ASD+ADHD: more general psychopathology (internalizing + externalizing symptoms) more impairments on the social interaction scale of the ADI-R Holtmann et al., 2005
6 ADHD comorbidity in ASD needs clinical attention ADHD symptoms in children with ASD associated with more severe oppositional, aggressive, and ASD symptoms can interfere with ability to benefit from psychosocial treatments Gadow, DeVincent, & Pomeroy, 2006
7 Medication options for ADHD in ASD Alpha Agonists (clonidine) Psychostimulants Atomoxetine Antipsychotics?
8 Clonidine Open label retrospective study (N=19) Improvement in reducing sleep initiation latency and night awakening, To a less degree improvement in ADHD, mood instability, and aggressiveness Ming et al Brain & Development 30 (2008)
9 Clonidine cross-over with placebo N=8 Improvement on ABC irritability Stereotypy, Hyperactivity Inappropriate speech Main side effects Drowsiness Decreased activity. Jaselskis et al (1992) J Clin Psychopharmacol. 12(5):322-7
10 Transdermal clonidine Plb cross-over trial N=9 Improvement on three subscales of the Ritvo-Freeman Real Life Rating Scale: social relationship to people affectual responses sensory responses Sedation and fatigue during the first 2 weeks of clonidine treatment Fankhauser et al, (1992). J Clin Psychiatry; 53(3):77-82
11 Clonidine conclusions Very few controlled data! Positive effects on sleep latency and hyperactivity? Is effect sedating or truly enhancing inattention?
12 Methylphenidate Historical data and beliefs negative Small studies support use of MPH in autism Anecdotal reports of a high frequency of adverse drug reactions including stereotypies and social withdrawal Quintana et al (1995), J Autism dev Disorders Handen et al (2000), J Autism Dev Disorders
13 RUPP Study of MPH in Children with ASD + Hyperactivity 72 children with autism, Asperger s, or PDDNOS and significant ADHD symptoms Design 7-day test dose period 4-week double blind cross-over trial of 3 dose levels (0.125, 0.25, 0.50 mg/kg/dose) of MPH t.i.d. and placebo in random order RUPP (2005) Arch Gen Psychiatry
14 Test-dose phase 6 out of 72 subjects were unable to tolerate > 2 dose levels of MPH and were dropped from the study 16 out of the remaining 66 subjects had intolerable adverse effects at the highest dose of MPH; entered modified crossover phase Irritability was the most common reason for intolerability
15 Cross-over phase 58/66 subjects completed the cross-over phase 7 subjects dropped out due to intolerable adverse effects Significant main effect of dose of MPH on the ABC hyperactivity subscale as rated by both teacher (p=0.009) and parent (P<0.001)
16 Cross-over phase: Other ABC Subscales Worsening of parent-rated social withdrawal at high-dose MPH (P<0.001) No changes in other subscales (irritability, stereotypy, inappropriate speech)
17 Categorical response Plb Low Medium High Asperger s/ PDDNOS (32%) (37%) (37%) (32%) (N=19) Autism (N=47) (13%) (28%) (32%) (26%)
18 Most common side effects of MPH in ASD Appetite decrease (24%) Difficulty falling asleep (18%) Emotional outburst (13%) Irritability (12%) Stomach discomfort (7%) Rupp, 2005
19 MPH RUPP summary Methylphenidate superior to placebo (effect sizes 0.20 to 0.54) on hyperactivity ABC (MTA: ) 35/72 (49%) responders. Discontinuation 18% (MTA: 1.4%) No effect on irritability, lethargy/social withdrawal, stereotypy, or inappropriate speech
20 Methylphenidate-secondary effects Hyperactivity and impulsivity improved more than inattention. No effects on ODD or stereotyped and repetitive behavior Effects on joint attention initiations, response to bids for joint attention, self-regulation, and regulated affective state (examined through direct observation) Jahromi et al, 2008; Posey et al, 2007
21 Atomoxetine
22 Direct on noradrenaline, indirect on dopamine % vs. baseline in prefrontale cortex Atomoxetine 1 mg/kg i.p Time (hours) Serotonin Dopamine Noradrenaline * P < 0.05 vs. baseline * * Data from rat study Bymaster et al.2002
23 Three open label studies; atomoxetine in ASD Posey, et al; Journal of Child & Adolescent Psychopharmacology, 16, 5, 2006; n=16, 75% improved on the CGI-I Troost, et al; Journal of Child & Adolescent Psychopharmacology, 16, 5, 2006; n=12, decreased with 44% measured by the ADHDRS Jou, et al; Journal of Child & Adolescent Psychopharmacology, 15, 2, 2005; n=20, 60% response
24 Placebo controlled cross-over study 6 weeks atx vs placebo (n=16) ATX superior to placebo (p=.043, effect size d=0.90). Arnold et al, 2006
25 A Randomized, Double-blind Comparison of Atomoxetine Hydrochloride and Placebo for Symptoms of Attention- Deficit/Hyperactivity Disorder in Children and Adolescents with Autism Spectrum Disorder Sponsored by Eli Lilly and company
26 RADAR study Dutch multi-center study (n=97) Children with ASD plus ADHD Atomoxetine versus placebo (8 weeks) Open label extension (16 weeks)
27 Study design SP I SP II SP III Screening / wash-out Atomoxetine 1.2 mg/kg/day Placebo Open-label atomoxetine* Attachment days 1 wk Visit 1 Visit 2 Visit 6 Visit 11 * 1.2 mg/kg/day; the dose may be lowered to 0.8 mg/kg/day
28 ADHD rating scale (p<.001) -1,2 MMRM LS-mean at endpoint (95% CI): Atomoxetine 31,6 (29,2-33,9); Placebo 38,3 (36,0-40,6)
29 Inattentive symptoms (p=.003) MMRM LS-mean at endpoint (95% CI): Atomoxetine 17,2 (15,9-18,4); Placebo 19,9 (18,7-21,1)
30 Hyperactive/impulsive symptoms (p<.001) MMRM LS-mean at endpoint (95% CI): Atomoxetine 14,5 (13,0-15,9); Placebo 18,4 ( ,7)
31 Teacher ADHD ratings (p=.077) LOCF LS-mean at endpoint (95% CI): Atomoxetine 15,1 (13,0-17,2); Placebo 17,8 (15,7-19,8)
32 Teacher hyperactivity ratings (p=.024) * LOCF LS-mean at endpoint (95% CI): Atomoxetine 6,8 (5,5-8,0); Placebo 8,8 (7,6-10,0)
33 Atomoxetine categorical response Very much + Much + Minimally + No change Minimally - Much - Very much - ATX 0% 20.9% 27.9% 37.2% 9.3% 4.7% 0% PLB 2.2% 6.5% 13.0% 65.2% 6.5% 6.5% 0%
34 Adverse events; ATX-Radar vs MPH-RUPP Appetite decrease (27.1%) Initial insomnia (6.3%) Feeling abnormal (4.2%) Agitation (2.1%) Abdominal pain (18.8%) RADAR Appetite decrease (24.2%) Difficulty falling asleep (18.2%) Emotional outburst (13.6%) Irritability (12.1%) Stomach or abdominal discomfort (7.6%) Rupp, 2005
35 Adverse events ADHD+ASD versus ADHD only Nausea (29%) Decreased appetite (27%) Headache (25%) Fatigue (23%) Abdominal pain upper (19%) Vomiting (15%) Early morning awakening (10%) RADAR, 2009 Nausea (10-11%) Decreased appetite (16%) Headache (19%) Fatigue (1-10%) Abdominal pain upper (18%) Vomiting (10-11%) Early morning awakening (0.1-1%) SPC Atomoxetine
36 Main conclusions of atomoxetine trial Atmoxetine is better than placebo Most effects in hyperactivity domain Not many true responders Less robust effects than ADHD as such Relatively well tolerated but more adverse events than in ADHD as such
37 Conclusions ADHD symptoms frequent in ASD ADHD symptoms important focus for treatment in ASD Both MPH and ATX effective treatments, but not for every child! Children with ASD show less predictable, less robust response, and tend to experience more side effects
38 Future focus Effective treatments for non-responders Identification of treatment moderators Effectiveness of combined treatments Better treatments!!
39 What about antipsychotics? Risperidone Aripiprazole
40 Risperidon for irritability (Rupp, 2002) Multisite, randomized, double-blind trial of risperidone versus placebo Autistic disorder accompanied by severe tantrums, aggression, or selfinjurious behavior N=101 (5 to 17 years old) Mean daily dose 1.8±0.7 mg (range, )
41 Decrease in irritability
42 CGI Improvement status
43 Risperidone for core symptoms of autism? Improvements in restricted, repetitive, and stereotyped patterns of behavior, interests, and activities No change in social interaction and communication. McDougle et al, 2005
44 Risperidone effective on longer term Double-blind discontinuation after 24 weeks of treatment; placebo switch versus continuing use of risperidone Risperidone superior in preventing relapse: in 3 of 12 patients (25%) continuing on risperidone versus 8 of 12 (67%) switched to placebo (Troost et al, 2005) Rupp (2005): 12.5% (risperidone) versus 62.5% (placebo)
45 Cognitive effects of risperidone: sedation or enhancement No deterioriation of focused attention Improvement of divided attention Troost et al., 2006 Better on a verbal learning task (word recognition and spatial memory task). No deterioration. Amman et al., 2008
46
47 Side effects of risperidone may be genetically based Weight gain: 5HT2C promoter T allele carriers (22%): BMI z scores ( kg) Non-T carriers z ( kg) Hoekstra et al (under review) Prolactin elevation: Positively associated with number of functional CYP2D6 genes Troost et al, 2007
48 Aripiprazole for irritability N=218 8 weeks: placebo/5/10/15 mg (fixed dose) Decrease in ABC-I: (5-15 mg ari) vs 8.4 (plb) Weight gain 1.3 kg vs placebo 0.3 kg (risperidone RUPP 2.7 vs 0.8 kg) Marcus et al, 2009
49 Aripiprazole-flexible dose N=98; 8 weeks Placebo or aripirazole (5-15 mg) 12.9 vs 5.0 decrease ABC-I (Rupp risperidone 14.9 vs 3.6) Weight gain 2.0 vs 0.8 kg Owen et al., 2009
Alpha-2 Agonists. Antipsychotics
Table 5: Randomized Controlled Trials of Psychotropic Medications in Children and Adolescents with ASD Agent Study Target Symptoms Dose Demographics Significant Side Clonidine Guanfacine Jaselskis et al.,
More informationPsychopharmacology of Autism Spectrum Disorder
Psychopharmacology of Autism Spectrum Disorder Christopher J. McDougle, MD Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral Hospital
More information3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM. Autism Spectrum Disorder
Cynthia King, MD Associate Professor of Psychiatry UNMSOM Autism Spectrum Disorder 1 Identify three behavioral health concerns in ASD Identify three common families of medication that may be supportive
More information3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM
Cynthia King, MD Associate Professor of Psychiatry UNMSOM 1 2 Autism Spectrum Disorder 3 Identify three behavioral health concerns in ASD Identify three common families of medication that may be supportive
More informationDevelopmental Disorders
Pharmacology of Pervasive Developmental Disorders W. David Lohr, M.D. Assistant Professor Child Psychiatry Bingham Child Guidance Center University of Louisville School of Medicine 502-852-1065 wdlohr01@louisville.edu
More informationPediatrics Grand Rounds 9 April University of Texas Health Science Center at San Antonio. Overview. Prevalence of ASD (Cont.) Prevalence of ASD
9 April 200 Overview Diagnosis and Treatment of Autism Spectrum Disorders Steven R. Pliszka, M.D. Professor and Vice Chair Chief, Division of Child and Adolescent Psychiatry Department of Psychiatry The
More information11/2/2016 INSIDE THE MIND OF A CHILD PSYCHIATRIST: PROBLEM BEHAVIORS IN CHILDREN WITH AUTISM FACULTY DISCLOSURE
FACULTY DISCLOSURE INSIDE THE MIND OF A CHILD PSYCHIATRIST: PROBLEM BEHAVIORS IN CHILDREN WITH AUTISM KristinDawson, MD Assistant Professor University of Kentucky No commercial conflicts of Interest Salary
More informationPharmacological management in children and adolescents with pervasive developmental disorder
Pharmacological management in children and adolescents with pervasive developmental disorder Min Sung, Daniel S. S. Fung, Yiming Cai, Yoon Phaik Ooi Objective: Pervasive developmental disorder (PDD) is
More informationPiecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder
Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder Hannah Sauer, PharmD PGY1 Pediatric Pharmacy Resident Mayo Clinic 2015 MFMER slide-1 Objectives
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBX
CT Registry ID#7068 Page 1 Summary ID# 7068 Clinical Study Summary: Study B4Z-MC-LYBX A Randomized, Double-Blind Comparison of Hydrochloride and Placebo in Child and Adolescent Outpatients with Attention-
More informationTreatment of Autism Spectrum Disorder in Children and Adolescents
Evidence-Based Medicine Key Words: autism spectrum disorder, treatment, psychotherapy, psychopharmacology Treatment of Autism Spectrum Disorder in Children and Adolescents By Melissa DeFilippis, Karen
More informationTreatment for Co-Occurring Attention Deficit/Hyperactivity Disorder and Autism Spectrum Disorder
Neurotherapeutics DOI 10.1007/s13311-012-0126-9 REVIEW Treatment for Co-Occurring Attention Deficit/Hyperactivity Disorder and Autism Spectrum Disorder Naomi Ornstein Davis Scott H. Kollins # The American
More informationMedications in Autism: What We Know and Don't Know
Medications in Autism: What We Know and Don't Know Jeremy Veenstra-VanderWeele, M.D. Mortimer D. Sackler, M.D., Associate Professor Center for Autism and the Developing Brain Sackler Institute for Developmental
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBU
CT Registry ID#7065 Page 1 Summary ID# 7065 Clinical Study Summary: Study B4Z-MC-LYBU A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride Augmented with Either Extended-Release Methylphenidate
More informationPsychopharmacology of Autism Spectrum Disorders
Psychopharmacology of Autism Spectrum Disorders Gabriel Kaplan, MD a,b, *, James T. McCracken, MD c KEYWORDS Autism spectrum disorders Autism Stimulants Irritability Repetitive behaviors Hyperactivity
More informationAutism Spectrum Disorders & Attention Deficit Disorder in PEDIATRIC PRIMARY CARE. Disclosures
Autism Spectrum Disorders & Attention Deficit Disorder in PEDIATRIC PRIMARY CARE TIPS Conference March 22, 2019 Benjamin L. Handen, PhD, BCBA-D Professor of Psychiatry and Pediatrics Western Psychiatric
More informationWhat About Health 3: Challenging Behaviors
The title of this presentation is What About Health. I m. In this presentation I will discuss a number of health and mental health issues related to children with ASD. 1 Now I am going to switch to discussing
More informationJean Paul Richter, writer ( )
The words a father speaks to his children in the privacy of the home are not overheard at the time, but, as in whispering galleries, they will be clearly heard at the end and by posterity. Jean Paul Richter,
More informationAttention-Deficit/Hyperactivity Disorder Nathan J. Blum, M.D.
ADHD in Preschool Children Preschool ADHD: When Should We Diagnose it & How Should We Treat it? Professor of Pediatrics Diagnosis of ADHD in Preschool Children: Impact of DSM-IV Is Preschool ADHD Associated
More informationPharmacotherapy of ADHD with Non- Stimulants
Pharmacotherapy of ADHD with Non- Stimulants Timothy E. Wilens, M.D. Chief, Division of Child and Adolescent Psychiatry, (Co)Director of Center for Addiction Medicine, Massachusetts General Hospital Massachusetts
More information6/22/2012. Co-morbidity - when two or more conditions occur together. The two conditions may or may not be causally related.
Autism Spectrum Disorders and Co-existing Mental Health Issues By Dr. Karen Berkman Objective To present an overview of common psychiatric conditions that occur in persons with autism spectrum disorders
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYCL
CT Registry ID#8226 Page 1 Summary ID# 8226. Clinical Study Summary: Study B4Z-MC-LYCL Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine
More informationAlgorithm for Management of Irritability in Children and Adolescents with ASD: Pharmacotherapy
Algorithm for Management of Irritability in Children and Adolescents with ASD: Pharmacotherapy Dr. Dean Elbe, PharmD, BCPP Clinical Pharmacy Specialist, Child & Adolescent Mental Health November 16, 2016
More informationMedications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More informationPharmacotherapy of ADHD with Non-Stimulants
Pharmacotherapy of ADHD with Non-Stimulants Timothy E. Wilens, M.D. Chief, Division of Child and Adolescent Psychiatry, (Co)Director of Center for Addiction Medicine, Massachusetts General Hospital Massachusetts
More informationSummary ID# Clinical Study Summary: Study B4Z-JE-LYBC
CT Registry ID# 5285 Page 1 Summary ID# 5285 Clinical Study Summary: Study B4Z-JE-LYBC A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Hydrochloride
More informationBiomedical and Vocational Interventions for Adults with Autism
Biomedical and Vocational Interventions for Adults with Autism Robert L Hendren, DO Professor of Psychiatry and Behavioral Science Integration of Adults with Autism into the Whole of Society People With
More informationAutism Spectrum Disorder and Mental Health Challenges in Youth
Autism Spectrum Disorder and Mental Health Challenges in Youth Management in the Primary Care Setting February 13, 2016 Rebecca Marshall, MD, MPH Outline DSM V Criteria Comorbidities Behavioral treatments
More informationDisclosures. Autism Society of Wisconsin. Case 2. Case 1. Case 3. Case 4 3/29/2018. Medication treatment for people with Autism Spectrum Disorder
Medication treatment for people with Autism Spectrum Disorder Autism Society of Wisconsin April 20, 2018 Richard P. Barthel, M.D. Disclosures In accordance with the ACCME policy on relevant financial disclosure,
More informationSYNOPSIS INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER (FOR NATIONAL AUTHORITY USE ONLY) Volume: Page:
SYNOPSIS Risperdal Risperidone (R064766) Protocol No.: RIS-USA-150 Part 1 INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER AUTHORITY USE ONLY) Title of Study: A Double-Blind, Placebo-Controlled
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYAX
CT Registry ID#5004 Page 1 Summary ID# 5004 Clinical Study Summary: Study B4Z-MC-LYAX A Randomized, Double-Blind, Placebo-Controlled Study of Hydrochloride in Adolescents with Attention-Deficit/Hyperactivity
More informationAtomoxetine. Open study showed 60% response of inattention and hyperactivity with a few much worse (Jou et al 2005)
Atomoxetine Open study showed 60% response of inattention and hyperactivity with a few much worse (Jou et al 2005) Buspirone Case reports (McCormick 1997, Hillbrand and Scott 1995,Realmuto et al 1989,
More informationAttention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6
in Children under Age 6 Level 0 Conduct comprehensive assessment and provide psychoeducation about ADHD, including clearly defined treatment expectations. Consider co-morbid developmental language disorder,
More informationCurrent. Drug therapy algorithms target autism s problem behaviors. p SYCHIATRY. Having an evidence-based game plan. can help you manage maladaptive
2 Drug therapy algorithms target autism s problem behaviors Having an evidence-based game plan can help you manage maladaptive behaviors that are holding back children or adults with autism. Kimberly A.
More informationProfessor Alasdair Vance Head, Academic Child Psychiatry Department of Paediatrics University of Melbourne Royal Children s Hospital
Attention Deficit Hyperactivity Disorder: an update on biological risk factors and a pharmacological treatment approach Professor Alasdair Vance Head, Academic Child Psychiatry Department of Paediatrics
More informationAutism/Pervasive Developmental Disorders Update. Kimberly Macferran, MD Pediatric Subspecialty for the Primary Care Provider December 2, 2011
Autism/Pervasive Developmental Disorders Update Kimberly Macferran, MD Pediatric Subspecialty for the Primary Care Provider December 2, 2011 Overview Diagnostic criteria for autism spectrum disorders Screening/referral
More informationSummary ID#2552. Clinical Study Summary: Study B4Z-MC-LYAF (Final Report, Study Period III Visit Group II Study Period IV)
CT Registry ID# 2552 Page 1 Summary ID#2552 Clinical Study Summary: Study B4Z-MC-LYAF (Final Report, Study Period III Visit Group II Study Period IV) Relapse Prevention after 10-Week and 52-Week Treatment
More informationThere are two things to aim at in life; first to get what you want, and after that to enjoy it. Only the wisest of mankind achieve the second.
There are two things to aim at in life; first to get what you want, and after that to enjoy it. Only the wisest of mankind achieve the second. Logan Pearsall Smith, essayist (1865-1946) Learning Objectives
More informationAggression (Severe) in Children under Age 6
Aggression (Severe) in Children under Age 6 Level 0 Comprehensive diagnostic assessments. Refer to Principles of Practice on page 6. Evaluate and treat comorbid conditions (i.e. medical, other psychiatric
More informationCOMORBIDITY PREVALENCE AND TREATMENT OUTCOME IN CHILDREN AND ADOLESCENTS WITH ADHD
COMORBIDITY PREVALENCE AND TREATMENT OUTCOME IN CHILDREN AND ADOLESCENTS WITH ADHD Tine Houmann Senior Consultant Child and Adolescent Mental Health Center, Mental Health Services Capital Region of Denmark
More informationPsychotropics in Learning Disabilities: Systematic reviews. Professor Shoumitro Deb FRCPsych, MD University of Birmingham
Psychotropics in Learning Disabilities: Systematic reviews Professor Shoumitro Deb FRCPsych, MD University of Birmingham HTA EVIDENCE CATEGORIES Type I: RCTs/ Meta analysis Type II: Other controlled studies
More informationA Prospective Open Trial of Guanfacine in Children with Pervasive Developmental Disorders
J. Child & Adolesc. Psychopharmacol. Vol. 16(5):589-598 (2006) ISSN: (print 1044-5463) (online 1557-8992) doi:10.1089/cap.2006.16.589. This is a peer reviewed pre-print version of the following article:
More informationChallenging ASD Cases November 11, Melanie Penner, MD, MSc, Mohammad Zubairi, MD, MEd,
Challenging ASD Cases November 11, 2017 Melanie Penner, MD, MSc, FRCPC @drmelpenner Mohammad Zubairi, MD, MEd, FRCPC @md_mszubairi Learning Objectives By the end of this workshop, participants will: 1)
More informationAtomoxetine (First known as Tomoxetine) (Adopted by the CCG until review and further notice)
New Medicine Report Document Status Atomoxetine (First known as Tomoxetine) (Adopted by the CCG until review and further notice) Post Suffolk D&TC Traffic Light Decision RED Date of Last Revision 12.07.04
More informationPerspective Truth on ADHD & Medications. Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry
Perspective Truth on ADHD & Medications Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry Disclosures National Institute of Health ADHD and Aggression Study Co- Investigator
More informationUsing Drugs to Improve the Behavior of People with Autism: A Skeptical Appraisal. Alan Poling, Ph.D., BCBA-D Western Michigan University
Using Drugs to Improve the Behavior of People with Autism: A Skeptical Appraisal Alan Poling, Ph.D., BCBA-D Western Michigan University In a 2010 study of 60,641 children Mandell et al. found that: 56%
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBR
CT Registry ID#6934 Page 1 Summary ID# 6934 Clinical Study Summary: Study B4Z-MC-LYBR Title of Study: A Randomized, Double-Blind Comparison, Safety and Efficacy Trial of Atomoxetine Hydrochloride and Methylphenidate
More informationADHD Explanation 5: Medications used in ADHD
ADHD Explanation 5: Medications The aim of treatment is efficient functioning and achieving goals in life It is most important to find the dose of medications that works best As children grow they may
More informationClinical Practice Pathways for Evaluation and Medication Choice for Attention-Deficit/Hyperactivity Disorder Symptoms in Autism Spectrum Disorders
SUPPLEMENT ARTICLE Clinical Practice Pathways for Evaluation and Medication Choice for Attention-Deficit/Hyperactivity Disorder Symptoms in Autism Spectrum Disorders AUTHORS: Rajneesh Mahajan, MD, a Maria
More informationMRCPsych Pharmacology of ADHD treatment. Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist
MRCPsych Pharmacology of ADHD treatment Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist 04 01 17 Curriculum mapping MRCPsych Paper A(ii) covers clinical psychopharmacology MRCPsych Syllabus:
More informationD I A G N O S I S ADD/ADHD. Conduct Disorder. Oppositional. Oppositional Defiant Disorder. Defiant. Anxiety Disorder. Adjustment.
Dr. Crismon has no potential conflicts of interest to disclose with regard to this presentation. M. Lynn Crismon, Pharm.D., FCCP, BCPP Dean James T. Doluisio Regents Chair & Behrens Centennial Professor
More informationUniversity of Groningen. Research on atomoxetine in Dutch ASD/ADHD children Harfterkamp, Maria
University of Groningen Research on atomoxetine in Dutch ASD/ADHD children Harfterkamp, Maria IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationScottish Medicines Consortium
Scottish Medicines Consortium atomoxetine capsules 10 mg to 60 mg (Strattera ) (153/05) Eli Lilly and Company Ltd No. 4 February 2005 The Scottish Medicines Consortium has completed its assessment of the
More information29 th Annual Learning Symposium
Friday, January 5, 9 Breakout Session 9 th Annual Learning Symposium ADHD & Medication Steven Pliszka, M.D. Dr. Steven Pliszka is a Dielmann Distinguished Professor and Chair of the Department of Psychiatry
More informationPsychiatric Medications. Positive and negative effects in the classroom
Psychiatric Medications Positive and negative effects in the classroom Teaching the Medicated Child Beverly Bryant, M.D. Hattiesburg Clinic 9/17/14 Introduction According to the National Survey of Children
More informationPharmacological interventions for children with Disruptive Behaviour Disorders or Conduct Disorder or Oppositional Defiant Disorder
updated 2012 Pharmacological interventions for children with Disruptive Behaviour Disorders or Conduct Disorder or Oppositional Defiant Disorder Q8: What is the effectiveness, safety and role of pharmacological
More informationADHD in the Preschool Aged Child
ADHD in the Preschool Aged Child (PATS) 11/2/2013 Stephen Meister MD, MHA, FAAP The Edmund N Ervin Pediatric Center (PATS) National Institute of Mental Health study First papers published in 2006 after
More informationDrug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Update 5 Report July 2015 The purpose of reports is to make available information regarding the comparative
More informationM Saccani 1*, E Buzzi 2, F Paccione 2. Licensee OAPL (UK) Creative Commons Attribution License (CC-BY) Effective Clinical Care.
Page 1 of 5 Effective Clinical Care The relationship between autism spectrum disorder and attentiondeficit hyperactivity disorder: A critical review of the effects of DSM 5 criteria and the implications
More informationStudy Center(s): The study was conducted at 39 study sites in Japan.
SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01
More informationAnxiety, Sleep & Attention - Treatment in Autism. Presentation Topics. Patient Case 5/4/2015
Anxiety, Sleep & Attention - Treatment in Autism Dr. Rowena Moore, CCC-SLPD Presentation Topics Patient case Behavioral Concerns Autism - Characteristics Autism - Management C.J. s Medications Literature
More informationBob Klaehn, M.D. Bob Klaehn, M.D. October 3, /30/14
Bob Klaehn, M.D. October 3, 2014 1 Bob Klaehn, M.D. Medical Director, Arizona Division of Developmental Disabilities since 2001 Faculty, MIHS Child Psychiatry Residency Program Child Psychiatrist, District
More informationManagement of ADHD in the Context of Autism Spectrum Disorder
Management of ADHD in the Context of Autism Spectrum Disorder Tolga Atilla Ceranoglu, MD F e a t u r e s o f A U T I S M CORE Features Impaired Social-Emotional Competence I. Non-verbal communication (NVC)
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 February 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 February 2009 ABILIFY 5 mg tablets, pack of 28 (CIP: 364 069-7) ABILIFY 10 mg tablets, pack of 28 (CIP: 364 073-4)
More informationIndications for Medications. John Wermager, MD May 2, 2017
Indications for Medications John Wermager, MD May 2, 2017 First and foremost, accurate diagnosis is imperative for good treatment. It may also guide a person to go down the medication route sooner, depending
More informationInterventions for Autism: Translating Research into Practice
Interventions for Autism: Translating Research into Practice Cindy Canceko Llego, MD, MSc Developmental-Behavioral Pediatrician Clinical Epidemiologist Objectives To discuss the importance of good scientific
More informationAutism: Practical Tips for Family Physicians
Autism: Practical Tips for Family Physicians Keyvan Hadad, MD, MHSc, FRCPC Alberta College of Family Physicians 61st Annual Scientific Assembly March 5, 2016 No conflict of interest Diagnosis and Misdiagnosis
More informationtopic : Co-Morbid Conditions by Cindy Ring, MSW, LSW and Michele LaMarche, BCBA
ABA Literature Summary e-newsletter OCTOBER 2011 ISSUE 5 topic : Co-Morbid Conditions by Cindy Ring, MSW, LSW and Michele LaMarche, BCBA 1. Co-Morbidity Rates and Types in Individuals with Autism............
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More informationOverview of ADHD Symptoms in ID/D
Overview of ADHD Symptoms in ID/D Laura Politte, M.D. Child and Adolescent Psychiatry Carolina Institute for Developmental Disabilities November 8, 2017 Define Define symptoms of ADHD, as defined by DSM-5
More informationSummary ID# Clinical Study Summary: Study B4Z-SB-LYDD
CT Registry ID# 9496 Page 1 Summary ID# 9496 Clinical Study Summary: Study B4Z-SB-LYDD An Open-label Study on Effectiveness and Tolerability of as Perceived by Patients, Parents, and Physicians in Children
More informationThe Adolescent with ADHD: Managing Transition
The Adolescent with ADHD: Managing Transition Professor Philip Hazell University of Sydney and Rivendell Child, Adolescent and Family Mental Health Service Disclosure Statement: Philip Hazell Source Eli
More informationTools that make a difference in mental health symptoms of autistic spectrum children Sumru Bilge-Johnson M.D. Program Director of Child Psychiatry
Tools that make a difference in mental health symptoms of autistic spectrum children Sumru Bilge-Johnson M.D. Program Director of Child Psychiatry Fellowship Associate Professor, Child Psychiatry NEOMED
More informationSupplementary Online Content
Supplementary Online Content Anagnostou E, Aman MG, Handen BL, et al. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autistic spectrum disorder:
More informationPHARMACOLOGICAL THERAPY OF AUTISM SPECTRUM DISORDERS IN THE CLINICAL PRACTICE
ANTON et al. ORIGINAL PAPERS PHARMACOLOGICAL THERAPY OF AUTISM SPECTRUM DISORDERS IN THE CLINICAL PRACTICE Andra ISAC 2, Magdalena KWASIUK 1, Roxana ȘIPOȘ 1, Ioana MICLUȚIA 1, Viorel LUPU 1, Elena PREDESCU
More informationManagement of Children With Autism Spectrum Disorders
CLINICAL REPORT Management of Children With Autism Spectrum Disorders Guidance for the Clinician in Rendering Pediatric Care Scott M. Myers, MD, Chris Plauché Johnson, MD, MEd, the Council on Children
More informationDisruptive behaviour disorders Oppositional defiant disorder (ODD) / Conduct disorder (CD)
Disruptive behaviour disorders Oppositional defiant disorder (ODD) / Conduct disorder (CD) Professor Alasdair Vance Head, Academic Child Psychiatry Department of Paediatrics University of Melbourne Royal
More informationUniversity of Texas Health Science Center at San Antonio. Pediatrics Grand Rounds 5 February History of stimulant treatment
Pharmacological Treatment of Attention Deficit Hyperactivity Disorder and its comorbidities Steven R. Pliszka, M.D. Professor and Vice Chair Chief, Division of Child and Adolescent Psychiatry Department
More informationCorrespondence should be addressed to Vitharon Boon-yasidhi;
Psychiatry Journal, Article ID 136158, 4 pages http://dx.doi.org/10.1155/2014/136158 Research Article Adverse Effects of Risperidone in Children with Autism Spectrum Disorders in a Naturalistic Clinical
More informationRisperidone use in children with autism carries heavy risks
NEWS Risperidone use in children with autism carries heavy risks BY EMILY ANTHES 28 APRIL 2014 1 / 6 Double edge: Risperidone can calm tantrums and aggression in some children with autism, but sleepiness
More informationKelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009
Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009 List the antipsychotics most often prescribed Compare and contrast the use and adverse effects experienced in the pediatric
More informationThe evidence for (or against) therapies in autism. With thanks to Danielle Wheeler and other systematic reviewers
The evidence for (or against) therapies in autism With thanks to Danielle Wheeler and other systematic reviewers Many different popular biomedical interventions Drug-based Complementary medicine Cochrane
More information28 th Annual Learning Symposium
Friday, January 6, 8 Breakout Session 8 th Annual Learning Symposium ADHD & Medication Steven Pliszka, M.D. Presented by: Steven Pliszka, M.D. Dielmann Distinguished Professor and Chair Department of Psychiatry,
More informationEvidence-Based Pharmacotherapy. Emily Harris, MD, MPH, FAAP Cincinnati Children s Hospital Medical Center
Evidence-Based Pharmacotherapy Emily Harris, MD, MPH, FAAP Cincinnati Children s Hospital Medical Center CME Disclosure I have no personal financial relationships in any commercial interest related to
More informationADHD:Updates and Practical Suggestions
:Updates and Practical Suggestions Elizabeth Reeve MD HealthPartners Medical Group Disclosure I have no financial disclosures I may be talking about non FDA approved indications for medications Elizabeth.A.Reeve@HealthPartners.com
More informationJennifer Zarcone. Kennedy Krieger Institute and Johns Hopkins School of Medicine
Jennifer Zarcone Kennedy Krieger Institute and Johns Hopkins School of Medicine 1 2 Estimated that between 20% to 45% of people with autism and ID are taking psychotropic medication 14% 30% are taking
More informationBipolar Disorder in Youth
Bipolar Disorder in Youth Janet Wozniak, M.D. Associate Professor of Psychiatry Director, Pediatric Bipolar Disorder Research Program Harvard Medical School Massachusetts General Hospital Pediatric-Onset
More information10/3/2016. Disclaimer. What is Autism? Autistic Behaviors
A novel evidence based ranking scale for medications and supplements in autism spectrum disorders Dan Rossignol MD FAAFP Rossignol Medical Center Florida Office (Melbourne, FL): 321.259.7111 California
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Shared Care Guideline for the prescribing and monitoring of antipsychotics for the treatment of Neurodevelopmental Disorders in children and adolescents. Scope: Version 1 Pennine
More information4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies
Child & Adolescent Behavioral Medicine & Medication Therapies Brian J Cowles, PharmD Associate Professor of Pharmacy Practice Albany College of Pharmacy & Health Sciences; Vermont Campus Behavioral Medicine
More informationChallenging Behavior and Psychotropic Medication: Evidence- Based Practices. Special Thanks. Evaluating Behavioral Effects of Psychotropic Medication
Challenging Behavior and Psychotropic Medication: Evidence- Based Practices Jennifer Zarcone Strong Center for Developmental Disabilities Supported by NICHD grant 26927 Special Thanks University of Kansas
More informationDrug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Report Update 3 September 2009 Update 2: November 2007 Update 1: May 2006 Original Report: September 2005 The
More informationPotential Treatment Targets in Autism Spectrum Disorder (ASD) James McCracken, MD UCLA.
Potential Treatment Targets in Autism Spectrum Disorder (ASD) James McCracken, MD UCLA Disclosures My spouse/partner and I have the following relevant financial relationship with a commercial interest
More informationMedication management in children and youth with ASD
Medication management in children and youth with ASD Evdokia Anagnostou, MD Clinician Scientist, Bloorview Research Institute Assistant Professor, Department of Pediatrics University of Toronto Disclosures
More informationAttention-Deficit/Hyperactivity Disorder in Adults with High-Functioning Pervasive Developmental Disorders in Japan
Open Journal of Psychiatry, 2014, 4, 372-380 Published Online October 2014 in SciRes. http://www.scirp.org/journal/ojpsych http://dx.doi.org/10.4236/ojpsych.2014.44043 Attention-Deficit/Hyperactivity Disorder
More informationManaging maladaptive behaviors in fragile X patients. Psychotropics can improve hyperactivity, anxiety, and aggression. For personal use only
For mass reproduction, content licensing and permissions contact Dowden Health Media. Managing maladaptive behaviors in fragile X patients Psychotropics can improve hyperactivity, anxiety, and aggression
More informationIntroduction to Magellan s Adopted Clinical Practice Guidelines for the Treatment of Children with Autism Spectrum Disorders
Introduction to Magellan s Adopted Clinical Practice Guidelines for the Treatment of Children with Autism Spectrum Disorders 1 Task Force Membership J. Andrew Burkins, M.D. Robert Ciaverelli, M.D. Kathleen
More informationPractice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder,
Practice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder, Journal of the Academy of Child and Adolescent Psychiatry, 1997 Primary Authors: Jon McClellan MD
More information